About Astec Lifesciences Limited
Data last updated: 19 May 2026
Astec Lifesciences Limited is a public limited company based in Mumbai, Maharashtra, India, a subsidiary of Godrej Agrovet Limited. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 25 January 1994, the company has been in operation for over 32 years.
Registered with ROC Mumbai under CIN L99999MH1994PLC076236. Listed on BSE: 533138 and NSE: ASTEC.
Capital: an authorised share capital of ₹25 Cr and a paid-up capital of ₹22.28 Cr. Formerly known as Urshila Traders Private Limited. It is led by directors including Ashok Vishwanath Hiremath and Rishinaradamangalam Govindan.
Last AGM: 28 July 2025. Financial statements filed for year ended 31 March 2025. Office: Godrej One 3Rd Floor Pirojshanagar Eastern Express Highway Vikhroli (East), Mumbai, Maharashtra, India – 400079.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹448.15 Cr, a growth of 17.53% compared to the previous year. The net worth stands at ₹390.92 Cr (up 66.34% YoY). Total assets are valued at ₹942.04 Cr (up 6.88% YoY).
The company has a workforce of approximately 615 employees as per the latest available data. It operates as a subsidiary of Godrej Agrovet Limited. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Astec Lifesciences. As per MCA filings, the company has satisfied charges of ₹467.94 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website astecls.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressGodrej One 3Rd Floor Pirojshanagar Eastern Express Highway Vikhroli (East), Mumbai, Maharashtra, India – 400079
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Astec Lifesciences Limited
Astec Lifesciences Limited has one previous CIN (Corporate Identification Number): U99999MH1994PLC076236. The current CIN is L99999MH1994PLC076236, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L99999MH1994PLC076236 | Current |
| U99999MH1994PLC076236 | Previous |
Associated Brands with Astec Lifesciences Limited
Astec Lifesciences Limited operates one associated brand: Astec LifeSciences. These brands represent Astec Lifesciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Organic intermediates are manufactured for pharmaceutical and agrochemical sectors. | astecls.com |
Competitors & Alternatives of Astec Lifesciences Limited
Brands and companies operating in the same space as Astec Lifesciences Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Hikal
|
APIs and intermediates are produced via custom synthesis and research. | Mumbai, India, India | 1988 |
Snapdragon Chemistry
|
Drug discovery and development service provider | Cambridge, United States, United States | 2014 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Business Activity of Astec Lifesciences Limited
Astec Lifesciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Astec Lifesciences Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Astec Lifesciences Limited
Astec Lifesciences Limited is audited by B S R & CO. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| B S R & CO. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Astec Lifesciences Limited
Astec Lifesciences Limited is currently managed by 10 directors, with 25 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
Financials of Astec Lifesciences Limited FY 2026 filings available
Astec Lifesciences Limited reported revenue of ₹448.15 Cr (up 17.53% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹448.15 Cr | ₹381.3 Cr | ₹458.18 Cr | ₹628.17 Cr | ₹676.57 Cr | ₹554.87 Cr | ₹522.61 Cr |
| Other Income | ₹5.07 Cr | ₹5.63 Cr | ₹5.64 Cr | ₹13.06 Cr | ₹10.47 Cr | ₹7.92 Cr | ₹11.93 Cr |
| Total Income | ₹453.22 Cr | ₹386.93 Cr | ₹463.82 Cr | ₹641.23 Cr | ₹687.03 Cr | ₹562.79 Cr | ₹534.54 Cr |
| Cost of Materials Consumed | ₹270.45 Cr | ₹248.86 Cr | ₹318.82 Cr | ₹460.83 Cr | ₹444.82 Cr | ₹344.6 Cr | ₹333.44 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹37.07 Lakh |
| Changes in Inventories | ₹27.96 Cr | ₹48.08 Cr | ₹45.7 Lakh | -₹59.59 Cr | -₹58 Cr | -₹2.55 Cr | ₹4.73 Cr |
| Employee Benefit Expense | ₹62.91 Cr | ₹61.1 Cr | ₹61.74 Cr | ₹52.26 Cr | ₹50.31 Cr | ₹38.35 Cr | ₹29.92 Cr |
| Finance Costs | ₹34.53 Cr | ₹36.7 Cr | ₹25.23 Cr | ₹20.71 Cr | ₹9.06 Cr | ₹4.75 Cr | ₹12.59 Cr |
| Depreciation & Amortisation | ₹44.92 Cr | ₹43.71 Cr | ₹36.25 Cr | ₹33.65 Cr | ₹34.36 Cr | ₹25.66 Cr | ₹23.16 Cr |
| Other Expenses | ₹91.35 Cr | ₹89.47 Cr | ₹83.07 Cr | ₹98.41 Cr | ₹85.37 Cr | ₹62.92 Cr | ₹68.97 Cr |
| Total Expenses | ₹532.12 Cr | ₹527.92 Cr | ₹525.57 Cr | ₹606.28 Cr | ₹565.91 Cr | ₹473.72 Cr | ₹473.19 Cr |
| Profit Before Exceptional Items & Tax | -₹78.91 Cr | -₹140.99 Cr | -₹61.75 Cr | ₹34.95 Cr | ₹121.13 Cr | ₹89.07 Cr | ₹61.35 Cr |
| Exceptional Items | -₹2.09 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹81 Cr | -₹140.99 Cr | -₹61.75 Cr | ₹34.95 Cr | ₹121.13 Cr | ₹89.07 Cr | ₹61.35 Cr |
| Total Tax Expense | -₹12.39 Lakh | -₹6.28 Cr | -₹14.86 Cr | ₹9.35 Cr | ₹31.24 Cr | ₹24 Cr | ₹13.83 Cr |
| Net Profit | -₹80.88 Cr | -₹134.71 Cr | -₹46.89 Cr | ₹25.59 Cr | ₹89.88 Cr | ₹65.07 Cr | ₹47.53 Cr |
| attributable to Owners | -₹80.92 Cr | -₹134.75 Cr | -₹46.93 Cr | ₹25.56 Cr | ₹89.86 Cr | ₹65.05 Cr | ₹47.51 Cr |
| attributable to NCI | ₹4.13 Lakh | ₹4.07 Lakh | ₹3.85 Lakh | ₹2.9 Lakh | ₹2.4 Lakh | ₹1.99 Lakh | ₹1.6 Lakh |
| Other Comprehensive Income | ₹46.17 Lakh | ₹17.38 Lakh | -₹58.58 Lakh | -₹21.82 Lakh | -₹72,000 | -₹18.4 Lakh | -₹17.06 Lakh |
| Total Comprehensive Income | -₹80.41 Cr | -₹134.54 Cr | -₹47.48 Cr | ₹25.38 Cr | ₹89.88 Cr | ₹64.88 Cr | ₹47.36 Cr |
| EBITDA (computed) | ₹54.49 Lakh | -₹60.58 Cr | -₹26.87 Lakh | ₹89.31 Cr | ₹164.54 Cr | ₹119.48 Cr | ₹97.11 Cr |
| Basic EPS | ₹-37.79 | ₹-68.71 | ₹-23.93 | ₹13.04 | ₹45.87 | ₹33.23 | ₹24.29 |
| Diluted EPS | ₹-37.79 | ₹-68.71 | ₹-23.93 | ₹13.04 | ₹45.85 | ₹33.21 | ₹24.27 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹942.04 Cr | ₹881.42 Cr | ₹974.93 Cr | ₹979.41 Cr |
| Non-current Assets | ₹499.05 Cr | ₹540.29 Cr | ₹576.44 Cr | ₹480.56 Cr |
| Current Assets | ₹442.99 Cr | ₹341.14 Cr | ₹398.49 Cr | ₹498.85 Cr |
| Property, Plant & Equipment | ₹423.58 Cr | ₹496.58 Cr | ₹353.46 Cr | ₹286.76 Cr |
| Inventories | ₹138.03 Cr | ₹159.81 Cr | ₹195.85 Cr | ₹294.85 Cr |
| Trade Receivables | ₹247.72 Cr | ₹147.44 Cr | ₹169 Cr | ₹154.9 Cr |
| Cash & Equivalents | ₹10.05 Cr | ₹57.54 Lakh | ₹47.15 Lakh | ₹47.34 Lakh |
| Equity (Net Worth) | ₹390.92 Cr | ₹235.02 Cr | ₹369.52 Cr | ₹419.56 Cr |
| Equity Share Capital | ₹22.28 Cr | ₹19.61 Cr | ₹19.61 Cr | ₹19.61 Cr |
| Borrowings (Non-current) | ₹50 Cr | ₹280 Cr | ₹199 Cr | ₹10.86 Cr |
| Borrowings (Current) | ₹398.93 Cr | ₹274.54 Cr | ₹294.89 Cr | ₹330.32 Cr |
| Total Debt (computed) | ₹448.93 Cr | ₹554.54 Cr | ₹493.89 Cr | ₹341.18 Cr |
| Current Liabilities | ₹499.79 Cr | ₹365.71 Cr | ₹397.16 Cr | ₹526.2 Cr |
| Total Liabilities | ₹551.12 Cr | ₹646.41 Cr | ₹605.41 Cr | ₹559.86 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹80.71 Cr | -₹8.4 Cr | ₹10.22 Cr | ₹74.66 Cr | ₹23.6 Cr |
| Investing Cash Flow | -₹4.31 Cr | -₹15.23 Cr | -₹135.18 Cr | -₹112.51 Cr | -₹103.87 Cr |
| Financing Cash Flow | ₹94.49 Cr | ₹23.73 Cr | ₹124.96 Cr | ₹37.77 Cr | ₹80.48 Cr |
| Capital Expenditure | ₹5.54 Cr | ₹21.82 Cr | ₹135.5 Cr | ₹117.26 Cr | ₹103.98 Cr |
| Free Cash Flow (computed) | -₹86.24 Cr | -₹30.22 Cr | -₹125.28 Cr | -₹42.6 Cr | -₹80.37 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹2.94 Cr | ₹2.94 Cr | ₹2.94 Cr |
| Net Change in Cash | ₹9.47 Cr | ₹10.39 Lakh | -₹19,000 | -₹8.11 Lakh | ₹21.57 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹158.62 Cr | ₹124.72 Cr | ₹73.72 Cr | ₹91.08 Cr | ₹213.39 Cr | ₹93.86 Cr | ₹98.55 Cr | ₹69.37 Cr | ₹153.75 Cr | ₹50.79 Cr | ₹110.79 Cr | ₹142.85 Cr |
| Other Income | ₹2.63 Cr | ₹81.52 Lakh | ₹1.12 Cr | ₹50.65 Lakh | ₹2.71 Cr | ₹1.91 Cr | ₹2 Cr | ₹92.37 Lakh | ₹2.05 Cr | ₹90.93 Lakh | ₹97.88 Lakh | ₹1.71 Cr |
| Total Income | ₹161.26 Cr | ₹125.54 Cr | ₹74.84 Cr | ₹91.59 Cr | ₹216.09 Cr | ₹95.77 Cr | ₹100.54 Cr | ₹70.3 Cr | ₹155.8 Cr | ₹51.7 Cr | ₹111.77 Cr | ₹144.56 Cr |
| Cost of Materials Consumed | ₹71.27 Cr | ₹81.65 Cr | ₹58.12 Cr | ₹59.41 Cr | ₹148.76 Cr | ₹63.31 Cr | ₹66.38 Cr | ₹33.71 Cr | ₹82.5 Cr | ₹43.17 Cr | ₹72.38 Cr | ₹120.77 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹39.06 Cr | ₹1.26 Cr | -₹16.84 Cr | ₹4.48 Cr | -₹13.65 Cr | -₹1.73 Cr | ₹13.85 Cr | ₹47.88 Cr | ₹22.82 Cr | -₹7.85 Cr | ₹3.64 Cr | -₹18.16 Cr |
| Employee Benefit Expense | ₹16.32 Cr | ₹15.78 Cr | ₹15.62 Cr | ₹15.18 Cr | ₹29.94 Cr | ₹15.52 Cr | ₹14.93 Cr | ₹16.23 Cr | ₹14.69 Cr | ₹14.43 Cr | ₹17.25 Cr | ₹15.38 Cr |
| Finance Costs | ₹7.92 Cr | ₹7.17 Cr | ₹8.4 Cr | ₹11.04 Cr | ₹20.32 Cr | ₹9.92 Cr | ₹9.33 Cr | ₹7.04 Cr | ₹6.67 Cr | ₹6.09 Cr | ₹5.99 Cr | ₹6.46 Cr |
| Depreciation & Amortisation | ₹11.77 Cr | ₹11.22 Cr | ₹10.44 Cr | ₹11.49 Cr | ₹22.98 Cr | ₹11.4 Cr | ₹11.47 Cr | ₹9.27 Cr | ₹9.01 Cr | ₹8.7 Cr | ₹9.16 Cr | ₹9.39 Cr |
| Other Expenses | ₹22.81 Cr | ₹22.04 Cr | ₹23.5 Cr | ₹23 Cr | ₹48.54 Cr | ₹22.5 Cr | ₹23.12 Cr | ₹17.81 Cr | ₹21.03 Cr | ₹19.38 Cr | ₹20.94 Cr | ₹21.73 Cr |
| Total Expenses | ₹169.16 Cr | ₹139.12 Cr | ₹99.24 Cr | ₹124.61 Cr | ₹256.9 Cr | ₹120.92 Cr | ₹139.09 Cr | ₹131.94 Cr | ₹156.72 Cr | ₹83.92 Cr | ₹129.36 Cr | ₹155.56 Cr |
| Profit Before Exceptional Items & Tax | -₹7.9 Cr | -₹13.58 Cr | -₹24.41 Cr | -₹33.02 Cr | -₹40.81 Cr | -₹25.15 Cr | -₹38.54 Cr | -₹61.64 Cr | -₹92.6 Lakh | -₹32.22 Cr | -₹17.6 Cr | -₹11.01 Cr |
| Exceptional Items | ₹0 | -₹2.09 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹7.9 Cr | -₹15.68 Cr | -₹24.41 Cr | -₹33.02 Cr | -₹40.81 Cr | -₹25.15 Cr | -₹38.54 Cr | -₹61.64 Cr | -₹92.6 Lakh | -₹32.22 Cr | -₹17.6 Cr | -₹11.01 Cr |
| Total Tax Expense | -₹15.31 Lakh | ₹1.02 Lakh | ₹96,000 | ₹94,000 | ₹15.64 Cr | ₹15.22 Cr | ₹80,000 | -₹21.92 Cr | ₹3.79 Lakh | -₹7.89 Cr | -₹4.18 Cr | -₹2.82 Cr |
| Net Profit | -₹7.75 Cr | -₹15.69 Cr | -₹24.42 Cr | -₹33.03 Cr | -₹56.45 Cr | -₹40.37 Cr | -₹38.55 Cr | -₹39.72 Cr | -₹96.39 Lakh | -₹24.33 Cr | -₹13.42 Cr | -₹8.19 Cr |
| attributable to Owners | -₹7.76 Cr | -₹15.7 Cr | -₹24.43 Cr | -₹33.04 Cr | -₹56.47 Cr | -₹40.38 Cr | -₹38.56 Cr | -₹39.72 Cr | -₹97.39 Lakh | -₹24.33 Cr | -₹13.43 Cr | -₹8.19 Cr |
| attributable to NCI | ₹1.03 Lakh | ₹1.01 Lakh | ₹1 Lakh | ₹1.09 Lakh | ₹2.14 Lakh | ₹1.28 Lakh | ₹1.01 Lakh | ₹92,000 | ₹1 Lakh | ₹82,000 | ₹1.17 Lakh | ₹86,000 |
| Other Comprehensive Income | ₹21.03 Lakh | ₹13.8 Lakh | ₹5.64 Lakh | ₹5.35 Lakh | -₹23.75 Lakh | ₹28,000 | ₹40.87 Lakh | ₹27,000 | -₹55.8 Lakh | -₹86,000 | -₹1.55 Lakh | -₹37,000 |
| Total Comprehensive Income | -₹7.54 Cr | -₹15.55 Cr | -₹24.36 Cr | -₹32.97 Cr | -₹56.68 Cr | -₹40.37 Cr | -₹38.14 Cr | -₹39.71 Cr | -₹1.52 Cr | -₹24.33 Cr | -₹13.43 Cr | -₹8.19 Cr |
| EBITDA (computed) | ₹11.79 Cr | ₹4.8 Cr | -₹5.57 Cr | -₹10.48 Cr | ₹2.49 Cr | -₹3.83 Cr | -₹17.74 Cr | -₹45.33 Cr | ₹14.76 Cr | -₹17.42 Cr | -₹2.44 Cr | ₹4.84 Cr |
| Basic EPS | ₹-3.48 | ₹-7.04 | ₹-11.35 | ₹-16.85 | ₹-28.79 | ₹-20.59 | ₹-19.66 | ₹-20.26 | ₹0.50 | ₹-12.41 | ₹-6.85 | ₹-4.18 |
| Diluted EPS | ₹-3.48 | ₹-7.04 | ₹-11.34 | ₹-16.85 | ₹-28.79 | ₹-20.59 | ₹-19.66 | ₹-20.26 | ₹0.50 | ₹-12.41 | ₹-6.85 | ₹-4.18 |
| Segment · Q4 FY25 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Within India | ₹46.16 Cr | ₹0 | ₹881.42 Cr | ₹646.35 Cr |
| Outside India | ₹164.07 Cr | ₹0 | ₹18,000 | ₹5.79 Lakh |
| Segment · FY 2025 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Within India | ₹119.6 Cr | ₹0 | - | - |
| Outside India | ₹258.55 Cr | ₹0 | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹448.15 Cr | ₹381.3 Cr | ₹458.18 Cr | ₹628.17 Cr | ₹676.57 Cr | ₹554.87 Cr | ₹522.22 Cr |
| Other Income | ₹4.99 Cr | ₹5.56 Cr | ₹5.58 Cr | ₹13.04 Cr | ₹10.46 Cr | ₹7.67 Cr | ₹11.93 Cr |
| Total Income | ₹453.13 Cr | ₹386.86 Cr | ₹463.76 Cr | ₹641.2 Cr | ₹687.03 Cr | ₹562.54 Cr | ₹534.15 Cr |
| Cost of Materials Consumed | ₹270.45 Cr | ₹248.86 Cr | ₹318.82 Cr | ₹460.83 Cr | ₹444.82 Cr | ₹344.6 Cr | ₹333.44 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹27.96 Cr | ₹48.08 Cr | ₹45.7 Lakh | -₹59.59 Cr | -₹58 Cr | -₹2.55 Cr | ₹4.73 Cr |
| Employee Benefit Expense | ₹62.91 Cr | ₹61.1 Cr | ₹61.74 Cr | ₹52.26 Cr | ₹50.31 Cr | ₹38.35 Cr | ₹29.92 Cr |
| Finance Costs | ₹34.57 Cr | ₹36.71 Cr | ₹25.24 Cr | ₹20.74 Cr | ₹9.09 Cr | ₹4.79 Cr | ₹12.64 Cr |
| Depreciation & Amortisation | ₹44.99 Cr | ₹43.77 Cr | ₹36.31 Cr | ₹33.71 Cr | ₹34.42 Cr | ₹25.71 Cr | ₹23.22 Cr |
| Other Expenses | ₹91.33 Cr | ₹89.46 Cr | ₹83.06 Cr | ₹98.4 Cr | ₹85.36 Cr | ₹62.97 Cr | ₹68.93 Cr |
| Total Expenses | ₹532.21 Cr | ₹527.98 Cr | ₹525.64 Cr | ₹606.35 Cr | ₹565.99 Cr | ₹473.87 Cr | ₹472.88 Cr |
| Profit Before Exceptional Items & Tax | -₹79.08 Cr | -₹141.12 Cr | -₹61.88 Cr | ₹34.85 Cr | ₹121.04 Cr | ₹88.67 Cr | ₹61.27 Cr |
| Exceptional Items | -₹2.09 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹81.17 Cr | -₹141.12 Cr | -₹61.88 Cr | ₹34.85 Cr | ₹121.04 Cr | ₹88.67 Cr | ₹61.27 Cr |
| Total Tax Expense | -₹16.31 Lakh | -₹6.31 Cr | -₹14.89 Cr | ₹9.33 Cr | ₹31.22 Cr | ₹23.98 Cr | ₹13.8 Cr |
| Net Profit | -₹81.01 Cr | -₹134.81 Cr | -₹46.99 Cr | ₹25.52 Cr | ₹89.82 Cr | ₹64.69 Cr | ₹47.47 Cr |
| Other Comprehensive Income | ₹48.49 Lakh | ₹16.88 Lakh | -₹56.92 Lakh | -₹22.88 Lakh | -₹54,000 | -₹17.62 Lakh | -₹18.21 Lakh |
| Total Comprehensive Income | -₹80.52 Cr | -₹134.64 Cr | -₹47.56 Cr | ₹25.29 Cr | ₹89.81 Cr | ₹64.52 Cr | ₹47.29 Cr |
| EBITDA (computed) | ₹48.34 Lakh | -₹60.64 Cr | -₹31.91 Lakh | ₹89.3 Cr | ₹164.55 Cr | ₹119.18 Cr | ₹97.14 Cr |
| Basic EPS | ₹-37.83 | ₹-68.74 | ₹-23.96 | ₹13.02 | ₹45.85 | ₹33.05 | ₹24.27 |
| Diluted EPS | ₹-37.83 | ₹-68.74 | ₹-23.96 | ₹13.02 | ₹45.83 | ₹33.02 | ₹24.25 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹941.22 Cr | ₹880.42 Cr | ₹974.15 Cr | ₹978.85 Cr |
| Non-current Assets | ₹499.56 Cr | ₹540.46 Cr | ₹576.67 Cr | ₹480.75 Cr |
| Current Assets | ₹441.66 Cr | ₹339.96 Cr | ₹397.48 Cr | ₹498.09 Cr |
| Property, Plant & Equipment | ₹423.38 Cr | ₹496.33 Cr | ₹353.24 Cr | ₹286.53 Cr |
| Inventories | ₹138.03 Cr | ₹159.81 Cr | ₹195.85 Cr | ₹294.85 Cr |
| Trade Receivables | ₹247.72 Cr | ₹147.44 Cr | ₹169 Cr | ₹154.9 Cr |
| Cash & Equivalents | ₹10.04 Cr | ₹56.5 Lakh | ₹46.05 Lakh | ₹45.65 Lakh |
| Equity (Net Worth) | ₹389.87 Cr | ₹234.07 Cr | ₹368.68 Cr | ₹418.79 Cr |
| Equity Share Capital | ₹22.28 Cr | ₹19.61 Cr | ₹19.61 Cr | ₹19.61 Cr |
| Borrowings (Non-current) | ₹50 Cr | ₹280 Cr | ₹199 Cr | ₹10.86 Cr |
| Borrowings (Current) | ₹398.93 Cr | ₹274.54 Cr | ₹294.89 Cr | ₹330.32 Cr |
| Total Debt (computed) | ₹448.93 Cr | ₹554.54 Cr | ₹493.89 Cr | ₹341.18 Cr |
| Current Liabilities | ₹499.78 Cr | ₹365.69 Cr | ₹397.25 Cr | ₹526.33 Cr |
| Total Liabilities | ₹551.36 Cr | ₹646.34 Cr | ₹605.47 Cr | ₹560.05 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹80.59 Cr | -₹8.39 Cr | ₹10.13 Cr | ₹74.32 Cr | ₹23.41 Cr |
| Investing Cash Flow | -₹4.32 Cr | -₹15.13 Cr | -₹134.98 Cr | -₹112.07 Cr | -₹103.57 Cr |
| Financing Cash Flow | ₹94.38 Cr | ₹23.62 Cr | ₹124.85 Cr | ₹37.66 Cr | ₹80.37 Cr |
| Capital Expenditure | ₹5.54 Cr | ₹21.82 Cr | ₹135.5 Cr | ₹117.26 Cr | ₹103.98 Cr |
| Free Cash Flow (computed) | -₹86.13 Cr | -₹30.21 Cr | -₹125.37 Cr | -₹42.94 Cr | -₹80.57 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹2.94 Cr | ₹2.94 Cr | ₹2.94 Cr |
| Net Change in Cash | ₹9.47 Cr | ₹10.45 Lakh | ₹40,000 | -₹8.81 Lakh | ₹21.52 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹158.62 Cr | ₹124.72 Cr | ₹73.72 Cr | ₹91.08 Cr | ₹213.39 Cr | ₹93.86 Cr | ₹98.55 Cr | ₹69.37 Cr | ₹153.75 Cr | ₹50.79 Cr | ₹110.79 Cr | ₹142.85 Cr |
| Other Income | ₹2.61 Cr | ₹79.36 Lakh | ₹1.09 Cr | ₹48.66 Lakh | ₹2.67 Cr | ₹1.89 Cr | ₹1.98 Cr | ₹90.7 Lakh | ₹2.03 Cr | ₹89.96 Lakh | ₹95.52 Lakh | ₹1.7 Cr |
| Total Income | ₹161.24 Cr | ₹125.51 Cr | ₹74.82 Cr | ₹91.57 Cr | ₹216.05 Cr | ₹95.75 Cr | ₹100.53 Cr | ₹70.28 Cr | ₹155.78 Cr | ₹51.69 Cr | ₹111.74 Cr | ₹144.55 Cr |
| Cost of Materials Consumed | ₹71.27 Cr | ₹81.65 Cr | ₹58.12 Cr | ₹59.41 Cr | ₹148.76 Cr | ₹63.31 Cr | ₹66.38 Cr | ₹33.71 Cr | ₹82.5 Cr | ₹43.17 Cr | ₹72.38 Cr | ₹120.77 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹39.06 Cr | ₹1.26 Cr | -₹16.84 Cr | ₹4.48 Cr | -₹13.65 Cr | -₹1.73 Cr | ₹13.85 Cr | ₹47.88 Cr | ₹22.82 Cr | -₹7.85 Cr | ₹3.64 Cr | -₹18.16 Cr |
| Employee Benefit Expense | ₹16.32 Cr | ₹15.78 Cr | ₹15.62 Cr | ₹15.18 Cr | ₹29.94 Cr | ₹15.52 Cr | ₹14.93 Cr | ₹16.23 Cr | ₹14.69 Cr | ₹14.43 Cr | ₹17.25 Cr | ₹15.38 Cr |
| Finance Costs | ₹7.93 Cr | ₹7.18 Cr | ₹8.41 Cr | ₹11.05 Cr | ₹20.32 Cr | ₹9.92 Cr | ₹9.34 Cr | ₹7.05 Cr | ₹6.68 Cr | ₹6.1 Cr | ₹6 Cr | ₹6.47 Cr |
| Depreciation & Amortisation | ₹11.79 Cr | ₹11.24 Cr | ₹10.46 Cr | ₹11.51 Cr | ₹23.01 Cr | ₹11.42 Cr | ₹11.49 Cr | ₹9.28 Cr | ₹9.02 Cr | ₹8.72 Cr | ₹9.17 Cr | ₹9.4 Cr |
| Other Expenses | ₹22.8 Cr | ₹22.03 Cr | ₹23.49 Cr | ₹23 Cr | ₹48.54 Cr | ₹22.5 Cr | ₹23.12 Cr | ₹17.8 Cr | ₹21.03 Cr | ₹19.37 Cr | ₹20.94 Cr | ₹21.72 Cr |
| Total Expenses | ₹169.18 Cr | ₹139.14 Cr | ₹99.27 Cr | ₹124.63 Cr | ₹256.93 Cr | ₹120.94 Cr | ₹139.1 Cr | ₹131.95 Cr | ₹156.74 Cr | ₹83.94 Cr | ₹129.38 Cr | ₹155.58 Cr |
| Profit Before Exceptional Items & Tax | -₹7.94 Cr | -₹13.63 Cr | -₹24.45 Cr | -₹33.06 Cr | -₹40.88 Cr | -₹25.18 Cr | -₹38.57 Cr | -₹61.67 Cr | -₹95.94 Lakh | -₹32.25 Cr | -₹17.64 Cr | -₹11.03 Cr |
| Exceptional Items | ₹0 | -₹2.09 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹7.94 Cr | -₹15.72 Cr | -₹24.45 Cr | -₹33.06 Cr | -₹40.88 Cr | -₹25.18 Cr | -₹38.57 Cr | -₹61.67 Cr | -₹95.94 Lakh | -₹32.25 Cr | -₹17.64 Cr | -₹11.03 Cr |
| Total Tax Expense | -₹16.31 Lakh | ₹0 | ₹0 | ₹0 | ₹15.62 Cr | ₹15.22 Cr | ₹0 | -₹21.93 Cr | ₹2.94 Lakh | -₹7.9 Cr | -₹4.19 Cr | -₹2.83 Cr |
| Net Profit | -₹7.78 Cr | -₹15.72 Cr | -₹24.45 Cr | -₹33.06 Cr | -₹56.5 Cr | -₹40.4 Cr | -₹38.57 Cr | -₹39.74 Cr | -₹98.88 Lakh | -₹24.35 Cr | -₹13.45 Cr | -₹8.21 Cr |
| Other Comprehensive Income | ₹21.73 Lakh | ₹15.48 Lakh | ₹5.64 Lakh | ₹5.64 Lakh | -₹23.64 Lakh | ₹0 | ₹40.89 Lakh | -₹37,000 | -₹55.8 Lakh | -₹37,000 | -₹38,000 | -₹37,000 |
| Total Comprehensive Income | -₹7.56 Cr | -₹15.56 Cr | -₹24.39 Cr | -₹33 Cr | -₹56.73 Cr | -₹40.4 Cr | -₹38.16 Cr | -₹39.74 Cr | -₹1.55 Cr | -₹24.35 Cr | -₹13.45 Cr | -₹8.21 Cr |
| EBITDA (computed) | ₹11.78 Cr | ₹4.79 Cr | -₹5.59 Cr | -₹10.5 Cr | ₹2.46 Cr | -₹3.85 Cr | -₹17.75 Cr | -₹45.34 Cr | ₹14.74 Cr | -₹17.43 Cr | -₹2.46 Cr | ₹4.83 Cr |
| Basic EPS | ₹-3.49 | ₹7.06 | ₹-11.39 | ₹-16.86 | ₹-28.81 | ₹-20.60 | ₹-19.67 | ₹-20.26 | ₹0.50 | ₹-12.42 | ₹-6.86 | ₹-4.19 |
| Diluted EPS | ₹-3.49 | ₹7.05 | ₹-11.39 | ₹-16.85 | ₹-28.81 | ₹-20.60 | ₹-19.67 | ₹-20.26 | ₹0.50 | ₹-12.42 | ₹-6.86 | ₹-4.19 |
Shareholding Pattern of Astec Lifesciences Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 71.97%, foreign institutional investors hold 0.02%, domestic institutional investors hold 3.34%, retail and other public shareholders hold 24.67% of Astec Lifesciences Limited. The company had 21,041 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jul 2025 | Jun 2025 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Promoters | 71.97% | 71.97% | 72.42% | 72.42% | 70.87% | 70.87% |
| Public | 28.03% | 28.03% | 27.58% | 27.58% | 29.13% | 29.13% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 71.97% | 70.87% | 66.75% | 66.77% | 65.29% | 65.23% | 71.33% | 67.62% | 67.31% | 65.54% | 63.64% |
| Public | 28.03% | 29.13% | 33.25% | 33.23% | 34.71% | 34.77% | 28.67% | 32.38% | 32.69% | 34.46% | 36.36% |
| Promoter change (YoY, %pts) | +1.10 | +4.12 | -0.02 | +1.48 | +0.06 | -6.10 | +3.71 | +0.31 | +1.77 | +1.90 | - |
Board & Governance of Astec Lifesciences Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Astec Lifesciences Limited has 8 directors - 4 independent and 1 executive. The board is chaired by Nadir B. Godrej.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Nadir B. Godrej | Non-Executive - Non Independent Director · Chairperson | 2015-10-12 | 5 |
| Ashok V. Hiremath | Non-Executive - Non Independent Director | 1994-01-25 | 2 |
| Burjis N. Godrej | Executive Director | 2022-07-25 | 2 |
| Rishinaradamangalam Ramakrishna Govindan | Non-Executive - Independent Director | 2020-01-30 | 1 |
| Nandkumar Dhekne | Non-Executive - Independent Director | 2020-12-18 | 3 |
| Anjali Rajesh Gupte | Non-Executive - Independent Director | 2020-12-18 | 2 |
| Ganapati Dadasaheb Yadav | Non-Executive - Independent Director | 2024-09-17 | 6 |
| Sunil Kataria | Non-Executive - Non Independent Director | 2025-09-01 | 2 |
| Committee | Members |
|---|---|
| Audit Committee | Rishinaradamangalam Ramakrishna Govindan (Chairperson), Ashok V. Hiremath, Anjali Rajesh Gupte |
| Nomination and remuneration committee | Rishinaradamangalam Ramakrishna Govindan (Chairperson), Sunil Kataria, Anjali Rajesh Gupte |
| Stakeholders Relationship Committee | Sunil Kataria (Chairperson), Nandkumar Dhekne, Rishinaradamangalam Ramakrishna Govindan |
| Risk Management Committee | Ashok V. Hiremath (Chairperson), Sunil Kataria, Rishinaradamangalam Ramakrishna Govindan |
| Corporate Social Responsibility Committee | Ashok V. Hiremath (Chairperson), Sunil Kataria, Rishinaradamangalam Ramakrishna Govindan |
Group Structure of Astec Lifesciences Limited
Astec Lifesciences Limited has 1 subsidiary company. This group structure data is as of FY 2025. The corporate group structure reflects Astec Lifesciences Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Behram Chemicals Pvt Ltd | U24100MH1993PTC071480 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Astec Lifesciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Apr 2015 | Ifci Limited | ₹15 Cr | Satisfied |
| 12 Nov 2014 | Others | ₹64 Cr | Satisfied |
| 13 Aug 2014 | Icici Bank Limited | ₹6.5 Cr | Satisfied |
| 13 Aug 2014 | Icici Bank Limited | ₹40 Cr | Satisfied |
| 11 Aug 2013 | Idbi Bank Limited | ₹10 Cr | Satisfied |
Total charge records: 31 View all charges
Employees and EPFO Compliance at Astec Lifesciences Limited
Astec Lifesciences Limited has a workforce of 615 employees as of Oct 09, 2025.
Employee and EPFO history for Astec Lifesciences Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Astec Lifesciences Limited
GST registrations and filing compliance for Astec Lifesciences Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Astec Lifesciences Limited
Credit ratings, litigation, and regulatory alerts for Astec Lifesciences Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Astec Lifesciences Limited
MSME payment history for Astec Lifesciences Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Astec Lifesciences Limited
Corporate group structure for Astec Lifesciences Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Astec Lifesciences Limited
MCA filings and documents for Astec Lifesciences Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Astec Lifesciences Limited
Recent News on Astec Lifesciences Limited
Frequently Asked Questions about Astec Lifesciences Limited
Astec Lifesciences Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 25 January 1994 (32+ years old) and is registered under CIN L99999MH1994PLC076236. Listed on BSE: 533138 and NSE: ASTEC. The company has 615 employees.
Astec Lifesciences Limited reported revenue of ₹448.15 Cr for FY 2026 (up 17.53% YoY) based on consolidated NSE filings.
The current directors of Astec Lifesciences Limited are:
- Ashok Vishwanath Hiremath - Director
- Rishinaradamangalam Govindan - Director
- Nandkumar Vasant Dhekne - Director
- Anjali Rajesh Gupte - Director
- Burjis Nadir Godrej - Additional Director
- Sunil Kataria - Director
- Arijit Mukherjee - Additional Director
- Ganapati Dadasaheb Yadav - Director
- Mathew Eipe - Additional Director
- Vishal Sharma - Additional Director
The primary industry of Astec Lifesciences Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Astec Lifesciences Limited is listed on both BSE (code: 533138) and NSE (symbol: ASTEC).
Astec Lifesciences Limited can be reached at the registered office: Godrej One 3Rd Floor Pirojshanagar Eastern Express Highway Vikhroli East, Mumbai, Maharashtra, India – 400079, or through the website astecls.com.